At the end of 2023, more than one-third of new prescriptions to treat Type 2 diabetes were GLP-1s, such as Mounjaro and Ozempic, among others, according to a study published April 15 in Annals of ...

People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper ...

The growing prevalence of diabetes, primarily due to obesity, aging populations, and sedentary lifestyles, is a key factor ...

Five scientists won this year’s Breakthrough Prize in Life Sciences for their work on GLP-1 and the development of drugs for diabetes and obesity.

Historical trends and future projections of the number of people with overweight and obesity suggest alarming parallel ...

The study finds better A1c lowering and weight reduction, but an expert clinician says practical issues may pose barriers.

Common Side Effects is, to be very forthright, the best work of sociopolitical commentary since Sean Baker's masterpiece Red Rocket — still the defining Trump-era movie — and Jordan Peele's Nope.

Talk of growth forecasts and self-imposed financial rules may feel very distant from you and your life, but the Spring Statement could affect both your job and your money. Here's what it could ...

We also observed that effects were attenuated among adults with diabetes. Mechanisms are beyond the scope of this study, but we speculate that this lack of effects among black adults and those with ...

Type 2 diabetes mellitus (T2DM ... 4 (DPP-4), the enzyme responsible for incretin degradation, leading to sustained incretin activity and improved insulinotropic effects. Influence on PYY and CCK ...

adults with type 1 diabetes treated with tirzepatide, a dual-incretin approved for use in individuals with type 2 diabetes associated with CVD and DKD. Satish Garg, MD, from the University of ...

Beyond the excitement, questions remain about its safety, long-term effects ... The drug also carries a risk of low blood sugar when combined with insulin or sulfonylureas. GIP and GLP-1 drugs work by ...